Scientists at Pennington Biomedical Research Center, along with a colleague from Peking University People's Hospital in China ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Waters (WAT – Research Report), Pharvaris ...

Morgan Stanley analyst Patrick Wood maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of ...

Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its price objective lowered by Canaccord Genuity Group from $57.00 to ...

Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented ... of glycemic control for people with diabetes taking it beyond 'superusers' and providing ...

To find out, the researchers accessed the TriNetX federated database, which includes data from 62 health care organizations in the U.S. Included in the data was whether a patient had type I or II ...

On Friday, Tandem Diabetes Care Inc (TNDM) stock saw a decline, ending the day at $30.6 which represents a decrease of $-2.72 or -8.16% from the prior close of $33.32. The stock opened at $33.71 and ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. We are living in exciting ...

During quarterly earnings calls across the medtech industry, a recurring question has been on investors’ minds: If ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0.36, expectations were $-0.4.

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Equities research analysts at Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM – Get Free ...